d his STN Search History

(FILE 'HOME' ENTERED AT 08:07:25 ON 04 MAR 2003)

FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DRUGLAUNCH, DRUGMONOG2, DRUGNL, DRUGUPDATES, ...' ENTERED AT 08:07:55 ON 04 MAR 2003

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, ...' ENTERED AT 08:08:28 ON 04 MAR 2003

SEA ORAL (S) (DELIVER### COMPOSITION ADMINIS####### DOS###) AND

0* FILE FEDRIP

L1 QUE ORAL (S) (DELIVER### COMPOSITION ADMINIS####### DOS###) AND

SEA ORAL (P) (DELIVER### COMPOSITION ADMINIS####### DOS###) AND

0* FILE ADISNEWS
0* FILE BIOCOMMERCE
0* FILE BIOTECHABS
0* FILE BIOTECHDS
0* FILE BIOTECHNO
0* FILE CEABA-VTB
0* FILE CIN
0* FILE ESBIOBASE
0* FILE FEDRIP
0* FILE FOMAD
0* FILE FOREGE
0* FILE FROSTI
0* FILE FSTA
0* FILE KOSMET
0* FILE MEDICONF
0* FILE NTIS
0* FILE NUTRACEUT
0* FILE PASCAL
0* FILE PHARMAML
0* FILE BABS
0* FILE CBNB

L2 QUE ORAL (P) (DELIVER### COMPOSITION ADMINIS####### DOS###) AND

SEA (ANTIMICROB#### OR ANTIBIOTIC OR CEPHALOSPORIN OR CEFTRIAX

4* FILE ADISCTI
2* FILE ADISINSIGHT
1* FILE ADISNEWS
4* FILE AGRICOLA
0* FILE ANABSTR
0* FILE AQUASCI
2* FILE BIOBUSINESS
1* FILE BIOCOMMERCE
45 FILE BIOSIS
33* FILE BIOTECHABS
33* FILE BIOTECHDS
21 FILE BIOTECHNO
6* FILE CABA
11 FILE CANCERLIT

```
            772   FILE CAPLUS
              5*  FILE CEABA-VTB
             17*  FILE CEN
              2   FILE CIN
              0*  FILE CONFSCI
              0*  FILE CROPB
             18*  FILE CROPU
             31*  FILE DDFB
             98*  FILE DDFU
              0*  FILE DGENE
             31*  FILE DRUGB
              0*  FILE DRUGLAUNCH
              0*  FILE DRUGMONOG2
              1*  FILE DRUGNL
            138*  FILE DRUGU
              1*  FILE DRUGUPDATES
              0*  FILE EMBAL
             62   FILE EMBASE
              6*  FILE ESBIOBASE
              7*  FILE FEDRIP
              0*  FILE FOMAD
              0*  FILE FOREGE
             10*  FILE FROSTI
              4   FILE FSTA
              1   FILE GENBANK
              0*  FILE HEALSAFE
            523*  FILE IFIPAT
            108*  FILE JICST-EPLUS
              7*  FILE KOSMET
              7*  FILE LIFESCI
             84   FILE MEDLINE
              1*  FILE NIOSHTIC
              0*  FILE NUTRACEUT
              0*  FILE OCEAN
             41*  FILE PASCAL
              4*  FILE PHARMAML
             21   FILE PHIN
            178*  FILE PROMT
             40   FILE SCISEARCH
              0*  FILE SYNTHLINE
            167   FILE TOXCENTER
          27057   FILE USPATFULL
            564   FILE USPAT2
              0*  FILE VETB
             11*  FILE VETU
            582   FILE WPIDS
            582   FILE WPINDEX
              2*  FILE BABS
             10*  FILE CBNB
             10*  FILE DIOGENES
            110*  FILE INVESTEXT
              1*  FILE IPA
              2   FILE NAPRALERT
L3             QUE (ANTIMICROB#### OR ANTIBIOTIC OR CEPHALOSPORIN OR CEFTRIAXO
               ---------

     FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, BIOTECHNO, SCISEARCH' ENTERED AT
     08:27:14 ON 04 MAR 2003
L4          1024 S L3
L5           156 S (ANTIMICROB#### OR ANTIBIOTIC OR  CEPHALOSPORIN OR CEFTRIAXON
L6             1 S L4 AND L5
```

```
L7            0 S L4 AND (CEPHALOSPORIN  OR CEFTRIAXONE) AND (METAL (S) CATION
L8           41 S L4 AND (CEPHALOSPORIN  OR CEFTRIAXONE) AND (METAL OR ZINC OR
L9           39 DUP REM L8 (2 DUPLICATES REMOVED)
L10          40 S L4 AND (METAL (S) CATION##)
L11          36 DUP REM L10 (4 DUPLICATES REMOVED)
L12          36 S L11 NOT L9

     FILE 'STNGUIDE' ENTERED AT 09:12:37 ON 04 MAR 2003
```

L1 QUE ORAL (S) (DELIVER### COMPOSITION ADMINIS####### DOS###) AND (ANTIMICRO B#### ANTIBIOTIC CEPHALOSPORIN CEFTRIAXONE)

L2 QUE ORAL (P) (DELIVER### COMPOSITION ADMINIS####### DOS###) AND (ANTIMICRO B#### ANTIBIOTIC CEPHALOSPORIN CEFTRIAXONE)

L3 QUE (ANTIMICROB#### OR ANTIBIOTIC OR CEPHALOSPORIN OR CEFTRIAXONE) AND (?P OLYMER OR CARRAGEENAN OR CHITOSAN OR PEG OR POLYETHYLENE OR LIPOSOM## OR BIOPOLYMER) AND (METAL (A) CATION OR METAL (S) CATION## OR ZINC OR CALCIUM)

L4 1024 L3

L5 156 (ANTIMICROB#### OR ANTIBIOTIC OR CEPHALOSPORIN OR CEFTRIAXONE) AND (ABSOR##### WITH ENHANC######)

L6 1 L4 AND L5

L7 0 L4 AND (CEPHALOSPORIN OR CEFTRIAXONE) AND (METAL (S) CATION##)

L8 41 L4 AND (CEPHALOSPORIN OR CEFTRIAXONE) AND (METAL OR ZINC OR CALCIUM)

L9 39 DUP REM L8 (2 DUPLICATES REMOVED)

L9 ANSWER 4 OF 39 CAPLUS COPYRIGHT 2003 ACS
TI An extended release pharmaceutical composition containing .beta.-lactam **antibiotics** with improved therapeutic efficacy
SO PCT Int. Appl., 16 pp.
CODEN: PIXXD2
IN Pendyala, Rama Rao; Khadgapathi, Podili; Nannapaneni, Venkaiah Chowdary; Pavuluri, Venkateswara Rao
L9 ANSWER 11 OF 39 CAPLUS COPYRIGHT 2003 ACS
TI Compositions and methods to improve the oral absorption of **antimicrobial** agents
SO PCT Int. Appl., 70 pp.
CODEN: PIXXD2
IN Choi, Seung-Ho; Lee, Jeoung-Soo; Keith, Dennis
L9 ANSWER 12 OF 39 CAPLUS COPYRIGHT 2003 ACS
TI Liquid composition of a biodegradable block **copolymer** for drug delivery system
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
IN Seo, Min-hyo; Choi, In-ja
L9 ANSWER 13 OF 39 CAPLUS COPYRIGHT 2003 ACS
TI Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2
IN Patel, Manesh V.; Chen, Feng-jing
L9 ANSWER 15 OF 39 CAPLUS COPYRIGHT 2003 ACS
TI Oil-in-water emulsion compositions for polyfunctional active ingredients
SO PCT Int. Appl., 82 pp.
CODEN: PIXXD2
IN Chen, Feng-jing; Patel, Mahesh V
L9 ANSWER 17 OF 39 CAPLUS COPYRIGHT 2003 ACS
TI Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
SO U.S., 141 pp., Cont.-in-part of U.S. Ser. No. 590,973, abandoned.
CODEN: USXXAM
IN Setterstrom, Jean A.; Van Hamont, John E.; Reid, Robert H.; Jacob, Elliot; Jeyanthi, Ramasubbu; Boedeker, Edgar C.; Mcqueen, Charles E.; Jarboe, Daniel L.; Cassels, Frederick; Brown, William; Thies, Curt; Tice, Thomas R.; Roberts, F. Donald; Friden, Phil
L9 ANSWER 18 OF 39 CAPLUS COPYRIGHT 2003 ACS
TI Complexes to improve oral absorption of poorly absorbable **antibiotics**
SO U.S., 9 pp.
CODEN: USXXAM
IN Choi, Seung-ho; Lee, Jeoung-soo
L9 ANSWER 20 OF 39 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI The possibility of clinical use of oral formulation of **Ceftriaxone**, the third generation **cephalosporin**.
SO Abstracts of the General Meeting of the American Society for Microbiology, (2001) Vol. 101, pp. 31. http://www.asmusa.org/mtgsrc/generalmeeting.htm. print.
Meeting Info.: 101st General Meeting of the American Society for Microbiology Orlando, FL, USA May 20-24, 2001
ISSN: 1060-2011.
AU Lee, J. (1); Kim, S.; Choi, S.
L9 ANSWER 21 OF 39 CAPLUS COPYRIGHT 2003 ACS
TI Production of **cephalosporin** C by immobilized cells of Cephalosporium acremonium
SO Indian Journal of Experimental Biology (2000), 38(11), 1134-1137
CODEN: IJEBA6; ISSN: 0019-5189

AU Ellaiah, P.; Chand, G. Murali; Srinivasulu, B.; Pardhasaradhi, S. V.
L9 ANSWER 25 OF 39 CAPLUS COPYRIGHT 2003 ACS
TI Method for stabilizing active substances for controlled release pharmaceutical formulation
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
IN Kofler, Bojan; Rebic, Ljubomira Barbara; Sirca, Judita; Venturini, Peter
L9 ANSWER 26 OF 39 CAPLUS COPYRIGHT 2003 ACS
TI Preparation of microsphere drug delivery systems
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
IN Wu, Xiao Yu; Liu, Zhi
L9 ANSWER 27 OF 39 CAPLUS COPYRIGHT 2003 ACS
TI Therapeutic treatment and prevention of infections with a bioactive material encapsulated within a biodegradable-biocompatible polymeric matrix
SO PCT Int. Appl., 363 pp.
CODEN: PIXXD2
IN Setterstrom, Jean A.; Van Hamont, John E.; Reid, Robert H.; Jacob, Elliot; Jeyanthi, Ramasubbu; Boedeker, Edgar C.; McQueen, Charles E.; Tice, Thomas R.; Roberts, F. Donald; Friden, Phil
L9 ANSWER 28 OF 39 CAPLUS COPYRIGHT 2003 ACS
TI Pharmaceutical composition for rapid suspension in aqueous media
SO PCT Int. Appl., 30 pp.
CODEN: PIXXD2
IN Calanchi, Massimo Maria; Marconi, Marco Giuseppe Raffaele; Mapelli, Luigi Giovanni

L9 ANSWER 29 OF 39 CAPLUS COPYRIGHT 2003 ACS
TI Pharmaceutical preparation comprising coated capsules or tablets containing a **liposome** powder encapsulating a drug
SO Eur. Pat. Appl., 10 pp.
CODEN: EPXXDW
IN Garces Garces, Josep; Bonilla Munoz, Angel; Parente Duena, Antonio
L9 ANSWER 32 OF 39 CAPLUS COPYRIGHT 2003 ACS
TI Controlled-release bioadhesive pharmaceutical compositions containing vinyl acetate-vinylpyrrolidone **copolymer**
SO Eur. Pat. Appl., 7 pp.
CODEN: EPXXDW
IN Rault, Isabelle; Pichon, Gerald
L9 ANSWER 33 OF 39 CAPLUS COPYRIGHT 2003 ACS
TI Compatibility of doxorubicin hydrochloride **liposome** injection with selected other drugs during simulated Y-site administration
SO American Journal of Health-System Pharmacy (1997), 54(23), 2708-2713
CODEN: AHSPEK; ISSN: 1079-2082
AU Trissel, Lawrence A.; Gilbert, Doward L.; Martinez, Juan F.

L9 ANSWER 36 OF 39 CAPLUS COPYRIGHT 2003 ACS
TI Solid pharmaceutical compositions for oral administration with prolonged gastric residence
SO Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW
IN Esposito, Pierandrea; Carli, Fabio

L9 ANSWER 37 OF 39 CAPLUS COPYRIGHT 2003 ACS
TI Controlled-release microparticle periodontal disease treatment system
SO Eur. Pat. Appl., 16 pp.
CODEN: EPXXDW
IN Baker, Richard W.

L9 ANSWER 39 OF 39 CAPLUS COPYRIGHT 2003 ACS

TI Dispenser for the sustained release of pharmaceuticals
SO Ger. Offen., 15 pp.
CODEN: GWXXBX
IN Eckenhoff, James B.; Cortese, Richard; Landrau, Felix A.

L9 ANSWER 37 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 1992:28178 CAPLUS
DN 116:28178
TI Controlled-release microparticle periodontal disease treatment system
IN Baker, Richard W.
PA Pharmetrix Corp., USA
SO Eur. Pat. Appl., 16 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 451390	A1	19911016	EP 1990-303916	19900411
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 2012665	AA	19910921	CA 1990-2012665	19900321
AU 629316	B2	19921001	AU 1990-52166	19900326
AU 9052166	A1	19911003		
JP 04005227	A2	19920109	JP 1990-101545	19900417
PRAI EP 1990-303916		19900411		

AB A controlled-release drug delivery system (for prophylactics, antiseptics, **antibiotics**, etc.) is provided for placement in the periodontal pocket, gingival sulcus, tooth socket, wound, or other cavity within the mouth. The system incorporates drug-contg. microparticles in a fluid carrier medium and is effective in the environment of use for .ltoreq.30 days. Polycarbonate microparticles contg. 18-35 wt.% tetracycline, 50-500 .mu.m in size, were capable of delivering tetracycline in a sustained fashion for periods of .apprx.25 h. Among the systems described are diffusion-controlled systems, erosion-controlled systems, a leaching-controlled system, and a combined diffusion/erosion-controlled system.

L9 ANSWER 36 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 1993:154582 CAPLUS
DN 118:154582
TI Solid pharmaceutical compositions for oral administration with prolonged gastric residence
IN Esposito, Pierandrea; Carli, Fabio
PA Vectorpharma International S.p.A., Italy
SO Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 526862	A1	19930210	EP 1992-113187	19920803
EP 526862	B1	19960214		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 134134	E	19960215	AT 1992-113187	19920803
ES 2086029	T3	19960616	ES 1992-113187	19920803
PRAI IT 1991-MI2212		19910806		

AB The title compns. comprise an active ingredient characterized by erratic gastrointestinal absorption, a high d. inorg. substance, such as BaSO4, Fe, Mg trisilicate, and a bioadhesive **polymer**, such as cellulose ethers and acrylate copolymers. For example, a tablet was formulated contg. nifedipine with micronized crosslinked PVP (1:5) 240, BaSO4 235, Methocel A4C 155, Aerosil 200 5, xanthan gum 30, galactomannan 30, and Mg stearate 5 mg.

L9 ANSWER 33 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 1997:795285 CAPLUS
DN 128:110395

TI Compatibility of doxorubicin hydrochloride **liposome** injection with selected other drugs during simulated Y-site administration
AU Trissel, Lawrence A.; Gilbert, Doward L.; Martinez, Juan F.
CS Division of Pharmacy, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030, USA
SO American Journal of Health-System Pharmacy (1997), 54(23), 2708-2713
CODEN: AHSPEK; ISSN: 1079-2082
PB American Society of Health-System Pharmacists
DT Journal
LA English
AB The compatibility of doxorubicin hydrochloride **liposome** injection with selected other drugs during simulated Y-site administration was studied. Five milliliters of doxorubicin hydrochloride **liposome** injection 0.4 mg/mL in 5% dextrose injection was combined with 5 mL of each of 82 other drugs in 5% dextrose injection or, if necessary to avoid incompatibilities with the diluent, 0.9% sodium chloride injection. The combinations were examd. with the unaided eye in fluorescent light and in high-intensity monodirectional light to enhance visualization of small particles and low-level turbidity. The turbidity of each combination was measured as well. Particle sizing and counting were performed on selected combinations. Evaluations were performed initially and at one and four hours. All combinations were stored at room temp. (.apprx.23 .degree.C). Most of the test drugs were compatible with doxorubicin hydrochloride **liposome** injection during the four-hour observation period. However, practitioners should be cautious in administering any drug simultaneously with doxorubicin hydrochloride **liposome** injection until the integrity of the **liposomes** can be verified. Eighteen drugs exhibited unacceptable increases or decreases in measured turbidity or particulate formation within four hours. During simulated Y-site administration, doxorubicin hydrochloride 0.4 mg/mL (as the **liposomal** injection) in 5% dextrose injection was compatible with 64 of 82 other drugs for four hours at .apprx.23 .degree.C and was incompatible with 18 of the test drugs.

L9 ANSWER 26 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 1998:742255 CAPLUS
DN 130:17234
TI Preparation of microsphere drug delivery systems
IN Wu, Xiao Yu; Liu, Zhi
PA Can.
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9850018	A1	19981112	WO 1998-CA419	19980506
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9872019	A1	19981127	AU 1998-72019	19980506
PRAI	US 1997-45710P	P	19970506		
	WO 1998-CA419	W	19980506		

AB A drug delivery compn. comprising microspheres contg. at least one chemotherapeutic agent and at least 1 chemosensitizer wherein the

microspheres have a biodegradable **polymer** matrix with functional groups which assoc. with the chemotherapeutic agent and chemosensitizer is described. Carboxymethyl dextran microspheres were prepd. and mixed with 1% verapamil or doxorubicin aq. soln. The microspheres showed sustained drug release.

L9 ANSWER 27 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 1998:527193 CAPLUS
DN 129:166193
TI Therapeutic treatment and prevention of infections with a bioactive material encapsulated within a biodegradable-biocompatible polymeric matrix
IN Setterstrom, Jean A.; Van Hamont, John E.; Reid, Robert H.; Jacob, Elliot; Jeyanthi, Ramasubbu; Boedeker, Edgar C.; McQueen, Charles E.; Tice, Thomas R.; Roberts, F. Donald; Friden, Phil
PA United States Dept. of the Army, USA; Van Hamont, John E.; et al.
SO PCT Int. Appl., 363 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 12

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9832427	A1	19980730	WO 1998-US1556	19980127
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 6309669	B1	20011030	US 1997-789734	19970127
	AU 9863175	A1	19980818	AU 1998-63175	19980127
PRAI	US 1997-789734	A	19970127		
	US 1984-590308	B1	19840316		
	US 1992-867301	A2	19920410		
	US 1995-446148	A2	19950522		
	US 1995-446149	B2	19950522		
	US 1996-590973	B2	19960124		
	WO 1998-US1556	W	19980127		

AB Novel burst-free, sustained release biocompatible and biodegradable microcapsules are disclosed which can be programmed to release their active core for variable durations ranging from 1-100 days in an aq. physiol. environment. The microcapsules are comprised of a core of polypeptide or other biol. active agent encapsulated in a matrix of poly(lactide/glycolide) **copolymer**, which may contain a pharmaceutically acceptable adjuvant, as a blend of upcapped free carboxyl end group and end-capped forms ranging in ratios from 100/0 to 1/99.

L9 ANSWER 29 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 1998:501150 CAPLUS
DN 129:166204
TI Pharmaceutical preparation comprising coated capsules or tablets containing a **liposome** powder encapsulating a drug
IN Garces Garces, Josep; Bonilla Munoz, Angel; Parente Duena, Antonio
PA Lipotec, S.A., Spain
SO Eur. Pat. Appl., 10 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	EP 855179	A2	19980729	EP 1997-500231	19971231
	EP 855179	A3	19990324		
	EP 855179	B1	20021113		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	ES 2130056	A1	19990616	ES 1997-73	19970116
	ES 2130056	B1	20000201		
	JP 10203964	A2	19980804	JP 1998-5926	19980114
PRAI	ES 1997-73	A	19970116		

AB A new pharmaceutical prepn. to improve the oral bioavailability of difficult-to-absorb drugs comprising capsules or tablets coated with enteric material contg. a freeze-dried or evapd. **liposome** powder incorporating a drug of pharmacol. benefit. A mixt. of 800 mg cholesterol and 800 mg hydrogenated lecithin was added to 1.25 g nimesulide (I) and heated at 60.degree. to obtain a suspension of **liposomes** incorporating I. The resulting **liposome** suspension was frozen and freeze-dried to obtain a freeze-dried prepn. which was placed in hard gelatin capsules (114 mg in each capsule). The resulting capsules were coated with Eudragit L by repeated immersion in a soln. of enteric **polymer** in isopropanol and subsequent drying in a current of air. The blood level of I in volunteers after 5 h was 7.31 as compared with 2.69 .mu.g/mL.

L9 ANSWER 17 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 2001:792223 CAPLUS
DN 135:348878
TI Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
IN Setterstrom, Jean A.; Van Hamont, John E.; Reid, Robert H.; Jacob, Elliot; Jeyanthi, Ramasubbu; Boedeker, Edgar C.; Mcqueen, Charles E.; Jarboe, Daniel L.; Cassels, Frederick; Brown, William; Thies, Curt; Tice, Thomas R.; Roberts, F. Donald; Friden, Phil
PA United States of America as Represented by the Secretary of the Army, USA
SO U.S., 141 pp., Cont.-in-part of U.S. Ser. No. 590,973, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 12

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6309669	B1	20011030	US 1997-789734	19970127
	US 5417986	A	19950523	US 1992-867301	19920410
	US 6410056	B1	20020625	US 1995-446148	19950522
	US 6447796	B1	20020910	US 1997-920326	19970821
	WO 9832427	A1	19980730	WO 1998-US1556	19980127
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9863175	A1	19980818	AU 1998-63175	19980127
PRAI	US 1984-590308	B1	19840316		
	US 1992-867301	A2	19920410		
	US 1995-446148	A2	19950522		
	US 1995-446149	B2	19950522		
	US 1996-590973	B2	19960124		
	US 1990-493597	B2	19900315		

	US 1990-521945	B2	19900511
	US 1991-690485	B2	19910424
	US 1991-805721	B2	19911121
	US 1994-209350	B2	19940107
	US 1994-242960	A2	19940516
	US 1996-675895	A2	19960705
	US 1996-698896	A2	19960816
	US 1997-789734	A2	19970127
	WO 1998-US1556	W	19980127

AB Novel burst-free, sustained-release biocompatible and biodegradable microcapsules which can be programmed to release their active core for variable durations ranging from 1-100 days in an aq. physiol. environment are disclosed. The microcapsules are comprised of a core of polypeptide or other biol. active agent encapsulated in a matrix of poly(lactide/glycolide) **copolymer**, which may contain a pharmaceutically-acceptable adjuvant, as a blend of upcapped free carboxyl end group and end-capped forms ranging in ratios from 100/0 to 1/99. Ampicillin microcapsules effectively prevented infection in 73% of rats whose wound were inoculated with ampicillin-resistant strains of Staphilococcus aureus, while systemic ampicillin failed in 100% of animals.

L9 ANSWER 18 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 2001:449182 CAPLUS
DN 135:51066
TI Complexes to improve oral absorption of poorly absorbable **antibiotics**
IN Choi, Seung-ho; Lee, Jeoung-soo
PA International Health Management Associates, Inc., USA
SO U.S., 9 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6248360	B1	20010619	US 2000-598089	20000621
WO 2001097851	A2	20011227	WO 2001-US19625	20010618
WO 2001097851	A3	20020516		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI	US 2000-598089	A	20000621
	US 2001-829405	A	20010409
	US 2001-283976P	P	20010416

AB The present invention provides compns. and methods for increasing absorption of poorly absorbable **antibiotics**, particularly third generation **cephalosporin antibiotics**, in oral dosage solid and/or suspension forms. Specifically, the compn. is comprised of a **biopolymer** that is preferably swellable and/or mucoadhesive, a poorly absorbable **antibiotic**, and a cationic binding agent contained within the **biopolymer** such that the binding agent is tonically bound or complexed to at least 1 member selected from the group consisting of the **biopolymer** and the **antibiotic**. A **ceftriaxone-carrageenan-calcium** complex was prepd. by the treatment of the **antibiotic** with **calcium**

and **carrageenan**. The plasma drug concn. from the complex was greater than that obtained by administering the **antibiotic** in an uncomplexed state.

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 20 OF 39 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AN 2002:176236 BIOSIS
DN PREV200200176236
TI The possibility of clinical use of oral formulation of **Ceftriaxone**, the third generation **cephalosporin**.
AU Lee, J. (1); Kim, S.; Choi, S.
CS (1) University of Utah, Salt Lake City, UT USA
SO Abstracts of the General Meeting of the American Society for Microbiology, (2001) Vol. 101, pp. 31. http://www.asmusa.org/mtgsrc/generalmeeting.htm. print.
Meeting Info.: 101st General Meeting of the American Society for Microbiology Orlando, FL, USA May 20-24, 2001
ISSN: 1060-2011.
DT Conference
LA English
AB Background: In order to evaluate the possibility of oral administration of **Ceftriaxone** (CTX) which is a poorly absorbed broad-spectrum third generation **cephalosporin** through the intestinal membrane, we prepared various oral formulations of CTX by combining CTX with mucoadhesive polymers using **metal** ion as binding agent. Mucoadhesive polymers that bind to the gastric mucin or epithelial cell surface are useful in drug delivery for the purpose of (a) retaining dosage forms in the GI tract and (b) increasing the intimacy and duration of contact of drug with the absorbing membrane. The bioavailability of oral formulations of CTX was investigated from each formulation. Method: Various oral formulations of CTX with mucoadhesive **polymer** were prepared by changing the ratio of **polymer** and **calcium** ion. **Carrageenan** (CG) and pectin (PT) was employed as mucoadhesive polymers. The formulations (40mg CTX equivalents/kg) were administered into the duodenum of male Sprague-Dawley rats (n=5) in order to bypass the stomach with capmul. Blood samples were taken at predetermined time intervals and CTX was bioassayed and analyzed by HPLC. Result: The i.v. and i.d. blood data were analyzed by Pharsight Winnonlin ver 3.0. In case of using CG, the bioavailability (%BA) value of CTX1-Ca0.2-CG4, CTX1-Ca0.5-CG4, CTX1-Ca1-CG4 and CTX1CG4 was 36.9, 6.1, 0, and 10.0%, respectively. In case of using PT, CTX1-Ca0.2-PT4, CTX1-Ca0.4-PT4, CTX1-Ca0.2-PT8, and CTX1PT4 was 40.6, 24.2, 13.8, and 29.9%, respectively. Bioavailability of the i.d. CTX (control) was 9.4%. Enhancing ratio was calculated from AUC for CTX1-Ca0.2-CG4, CTX1-Ca0.2-PT4 which were the best oral formulations of CTX against i.d. CTX. Value was 3.92; and 4.32, respectively. Conclusion: As with in vivo result, CTX1-Ca0.2-CG4 and CTX1-Ca0.2-PT4 significantly improved gastrointestinal absorption of CTX. Therefore these oral formulations of CTX are promising candidates for clinical use of CTX and other third generation **cephalosporins**

L9 ANSWER 21 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 2001:65840 CAPLUS
DN 134:325248
TI Production of cephalosporin C by immobilized cells of Cephalosporium acremonium
AU Ellaiah, P.; Chand, G. Murali; Srinivasulu, B.; Pardhasaradhi, S. V.
CS Pharmaceutical Biotechnology Division, Department of Pharmaceutical Sciences, Andhra University, Visakhapatnam, 530 003, India
SO Indian Journal of Experimental Biology (2000), 38(11), 1134-1137
CODEN: IJEBA6; ISSN: 0019-5189
PB National Institute of Science Communication, CSIR

DT Journal
LA English
AB Cephalosporium acremonium ATCC 48272 cells were immobilized on various adsorbents and in various entrapment matrixes. The influence of the incubation period, the best immobilization technique and the optimum concns. of the selected matrixes were investigated. From the results of the repeated batch fermn. in shake flasks, a good level of **antibiotic** was maintained for a period of about 19 days using 4% **calcium** alginate and 1% glass wool as entrapment and adsorbent supports, resp.

L9 ANSWER 39 OF 39 CAPLUS COPYRIGHT 2003 ACS
AN 1987:541112 CAPLUS
DN 107:141112
TI Dispenser for the sustained release of pharmaceuticals
IN Eckenhoff, James B.; Cortese, Richard; Landrau, Felix A.
PA Alza Corp., USA
SO Ger. Offen., 15 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3626103	A1	19870212	DE 1986-3626103	19860801
	DE 3626103	C2	19980219		
	US 4684524	A	19870804	US 1985-763493	19850808
	ES 556303	A1	19871016	ES 1986-556303	19860619
	ES 556375	A1	19880401	ES 1986-556375	19860620
	GB 2178659	A1	19870218	GB 1986-18350	19860728
	GB 2178659	B2	19890913		
	JP 62039518	A2	19870220	JP 1986-178598	19860729
	JP 08018972	B4	19960228		
	GB 2178660	A1	19870218	GB 1986-18568	19860730
	GB 2178660	B2	19890906		
	DE 3625915	A1	19870219	DE 1986-3625915	19860731
	DE 3625915	C2	19970424		
	JP 62039519	A2	19870220	JP 1986-181189	19860731
	JP 07059497	B4	19950628		
	AU 8660780	A1	19870212	AU 1986-60780	19860801
	AU 590308	B2	19891102		
	FR 2585950	A1	19870213	FR 1986-11370	19860806
	FR 2585950	B1	19890303		
	FR 2585951	A1	19870213	FR 1986-11371	19860806
	FR 2585951	B1	19890303		
	BR 8603756	A	19870310	BR 1986-3756	19860806
	ZA 8605914	A	19870429	ZA 1986-5914	19860806
	CA 1265966	A1	19900220	CA 1986-515469	19860807
	ZA 8605982	A	19870429	ZA 1986-5982	19860808
	AU 654515	B2	19941110	AU 1991-89738	19911216
PRAI	US 1985-763493	A	19850808		
	US 1984-590778	A2	19840319		
	US 1985-764143	A	19850809		

AB The title dispenser, such as a capsule, has a perforated wall and contains an active ingredient, a material m. at body temp. and an osmotically-active sol. compd. The chamber of a capsule contained a mass made of tetracycline-HCl 1000, **polyethylene** glycol 600 650, **polyethylene** glycol 1000 335, sorbitan monostearate 1.2, and 2,6-di-tert-butylcresol 0.02 mg, as well as a NaCl tablet placed on top of the mass. The wall was made of 90% cellulose acetate butyrate and 10% **polyethylene** glycol 400.

12 ANSWER 7 OF 36 CAPLUS COPYRIGHT 2003 ACS
AN 2001:434830 CAPLUS
DN 135:66028
TI Preparation of stabilized **antimicrobial** systems containing alcohol and metal oxides
IN Jampani, Hanuman; Holly, Thomas F.; Newman, Jerry L.
PA Ethicon, Inc., USA
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001041727	A1	20010614	WO 2000-US34008	20001213
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1152741	A1	20011114	EP 2000-984412	20001213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, IE, SI, LT, LV, FI, RO				

PRAI US 1999-460012 A 19991213
WO 2000-US34008 W 20001213

AB The present invention relates to high alc.-contg. **antimicrobial** compns. with improved stability of appearance and with methods of producing the same. An **antimicrobial** compn. comprises at least .apprx.50% vol./vol. alc., an effective amt. of a hydrophilic oil, an effective amt. of a **cationic antimicrobial** compd., and an effective amt. of a **metal** oxide, e.g., titanium dioxide and **zinc** oxide. The compn. further comprises effective amts. of humectants, phospholipids, and surfactants. A cationic **antimicrobial** compds. are selected from the group consisting of benzalkonium chloride, Me benzethonium chloride, benzethonium chloride, cetrimonium chloride, cetylpyridium chloride, polyhexamethylene biguanide, and chlorhexidine gluconate. For example, an **antimicrobial** gel was prepd. contg. (by wt.%) water 26.24, EtOH 21.90, PrOH 26.8, glycerol 5.0, propylene glycol 5.0, Plantaren 2000 3.60, Mackam CBS-50G 2.40, benzethonium chloride 1.0, Phospholipid CDM 1.50, PPG-40 diethylmonium chloride (Emcol CC-42) 1.20, hydroxypropyl cellulose 1.10, phenoxyethanol 1.00, glyceryl laurate 1.00, cetrimonium chloride (Varisoft 300) 0.86, isolene 0.50, Lambent Quat AD 0.50, fragrance 0.15, cetylpyridinium 0.10, ZnO 0.10, and Silsoft PEDM 0.05.

L12 ANSWER 8 OF 36 CAPLUS COPYRIGHT 2003 ACS
AN 2001:300486 CAPLUS
DN 134:331616
TI Sustained release microspheres based on a carrier protein, a water soluble **polymer** and complexing agents
IN Scott, Terrence L.; Brown, Larry R.; Riske, Frank J.; Blizzard, Charles D.; Rashba-Step, Julia
PA Epic Therapeutics, Inc., USA
SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001028524	A1	20010426	WO 2000-US28200	20001012
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6458387	B1	20021001	US 1999-420361	19991018
	EP 1223917	A1	20020724	EP 2000-973477	20001012
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
PRAI	US 1999-420361	A	19991018		
	WO 2000-US28200	W	20001012		

AB A microsphere compn. for sustained release of therapeutic or diagnostic agents comprises (1) a carrier protein, (2) a water-sol. **polymer**, (3) a polyanionic polysaccharide as a first complexing agent, and (4) a divalent **metal cation** (Ca and Mg) as a second complexing agent. The microspheres have a smooth surface that includes a plurality of channel openings that are < 1000 .ANG. in diam. Various drugs were encapsulated into microspheres. For example, microspheres contg. leuprolide acetate were prepd. using human serum albumin (HSA), dextran sulfate, **polyethylene** glycol, and polyvinylpyrrolidone. The microspheres were composed of approx. 10% leuprolide acetate, 50% human serum albumin, 20% dextran sulfate and 20% **polyethylene** glycol/polyvinylpyrrolidone. Similar particles were prepd. which also included **zinc** sulfate or caprylic acid, both of which retarded the release of protein and peptide from the microspheres. Also, rifampicin-contg. HSA microspheres were prepd. with HSA incorporation of 74% and rifampicin incorporation into the particles of > 6.8%. The av. size of the particles was detd. to be 68 nm in diam.

L12 ANSWER 7 OF 36 CAPLUS COPYRIGHT 2003 ACS
AN 2001:434830 CAPLUS
DN 135:66028
TI Preparation of stabilized **antimicrobial** systems containing alcohol and metal oxides
IN Jampani, Hanuman; Holly, Thomas F.; Newman, Jerry L.
PA Ethicon, Inc., USA
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001041727	A1	20010614	WO 2000-US34008	20001213
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1152741	A1	20011114	EP 2000-984412	20001213
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, IE, SI, LT, LV, FI, RO				
PRAI	US 1999-460012	A	19991213		
	WO 2000-US34008	W	20001213		

L12 ANSWER 8 OF 36 CAPLUS COPYRIGHT 2003 ACS
AN 2001:300486 CAPLUS
DN 134:331616
TI Sustained release microspheres based on a carrier protein, a water soluble **polymer** and complexing agents
IN Scott, Terrence L.; Brown, Larry R.; Riske, Frank J.; Blizzard, Charles D.; Rashba-Step, Julia
PA Epic Therapeutics, Inc., USA
SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001028524	A1	20010426	WO 2000-US28200	20001012
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6458387	B1	20021001	US 1999-420361	19991018
	EP 1223917	A1	20020724	EP 2000-973477	20001012
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
PRAI	US 1999-420361	A	19991018		
	WO 2000-US28200	W	20001012		

L12 ANSWER 10 OF 36 CAPLUS COPYRIGHT 2003 ACS

AN 2000:98384 CAPLUS
DN 132:141718
TI **Antibiotic** toothpaste containing zeolite and metal ions
IN Barry, John E.; Trogolo, Jeffrey A.
PA B.F. Technologies L.L.C., USA
SO PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000006208	A1	20000210	WO 1999-US17089	19990727
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6123925	A	20000926	US 1998-123755	19980727
	AU 9955447	A1	20000221	AU 1999-55447	19990727
	EP 1100445	A1	20010523	EP 1999-941976	19990727
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	US 1998-123755	A	19980727		
	WO 1999-US17089	W	19990727		

L12 ANSWER 13 OF 36 CAPLUS COPYRIGHT 2003 ACS
AN 1999:492575 CAPLUS
DN 132:61488
TI Metal adsorption of **chitosan** derivatives containing a thiourea group and their **antimicrobial** activities
AU Baba, Y.; Noma, H.; Hoaki, K.
CS Department of Applied Chemistry, Faculty of Engineering, Miyazaki University, Miyazaki, 889-2192, Japan
SO Kichin, Kitosan Kenkyu (1999), 5(2), 142-143
CODEN: KKKEFB; ISSN: 1340-9778
PB Nippon Kichin, Kitosan Gakkai
DT Journal
LA Japanese

L12 ANSWER 20 OF 36 CAPLUS COPYRIGHT 2003 ACS
AN 1997:599286 CAPLUS
DN 127:239137
TI **Antimicrobial** compositions useful for medical applications
IN Capelli, Christopher C.
PA USA
SO U.S., 21 pp., Cont.-in-part of U. S. 5,326,567.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5662913	A	19970902	US 1994-268616	19940701
	US 5326567	A	19940705	US 1993-82168	19930628
	US 5607683	A	19970304	US 1995-483815	19950607
	WO 9601119	A1	19960118	WO 1995-US7866	19950628
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ,				

TM, TT
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

	AU 9529064	A1	19960125	AU 1995-29064	19950628
PRAI	US 1991-683436		19910410		
	US 1993-82168		19930628		
	US 1994-268616		19940701		
	WO 1995-US7866		19950628		

L12 ANSWER 24 OF 36 CAPLUS COPYRIGHT 2003 ACS
AN 1996:164023 CAPLUS
DN 124:212163
TI **Antimicrobial** compositions useful for medical applications
IN Capelli, Christopher C.
PA USA
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9601119	A1	19960118	WO 1995-US7866	19950628

W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

	US 5662913	A	19970902	US 1994-268616	19940701
	AU 9529064	A1	19960125	AU 1995-29064	19950628
PRAI	US 1994-268616		19940701		
	US 1991-683436		19910410		
	US 1993-82168		19930628		
	WO 1995-US7866		19950628		

L12 ANSWER 28 OF 36 CAPLUS COPYRIGHT 2003 ACS
AN 1977:497756 CAPLUS
DN 87:97756
TI Elementary steps and dynamic aspects of carrier-mediated cation transport through membranes: the streptogramin **antibiotics** (group B)
AU Grell, E.; Oberbaeumer, I.; Ruf, H.; Zingsheim, H. P.
CS Max-Planck-Inst. Biophys. Chem., Goettingen, Fed. Rep. Ger.
SO FEBS-Symposium (1977), 42(Biochem. Membr. Transp.), 147-78
CODEN: FEBSDB; ISSN: 0071-4402
DT Journal
LA English
L12 ANSWER 29 OF 36 CAPLUS COPYRIGHT 2003 ACS
AN 1975:474016 CAPLUS
DN 83:74016
TI Dynamic properties and membrane activity of ion specific **antibiotics**
AU Grell, E.; Funck, Th.; Eggers, F.
CS Max-Planck-Inst. Biophys. Chem., Goettingen, Fed. Rep. Ger.
SO Mol. Mech. Antibiot. Action Protein Biosynth. Membr., Proc. Symp. (1972), Meeting Date 1971, 646-85. Editor(s): Munoz, E.; Garcia-Ferrandiz, F.; Vazquez, D. Publisher: Elsevier, Amsterdam, Neth.
CODEN: 30QGA7
DT Conference
LA English

L12 ANSWER 31 OF 36 CAPLUS COPYRIGHT 2003 ACS
AN 1969:21199 CAPLUS
DN 70:21199
TI **Antimicrobial** detergent compositions
IN Parran, John J., Jr.
PA Procter and Gamble Co.
SO Fr., 9 pp.
CODEN: FRXXAK
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI FR 1506349		19671222		
PRAI US		19650730		

L12 ANSWER 32 OF 36 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AN 2003:32107 BIOSIS
DN PREV200300032107
TI **Antimicrobial** hydrogel forming absorbent polymers and process for making the same.
AU Nakamura, Reiko (1); Hsueh, Kesyin Fugger; Benvegnu, Fernando; Fujioka, Kohtaro
CS (1) Hyogo, Japan Japan
ASSIGNEE: The Procter & Gamble Company
PI US 6476104 November 05, 2002
SO Official Gazette of the United States Patent and Trademark Office Patents, (Nov. 5 2002) Vol. 1264, No. 1, pp. No Pagination.
http://www.uspto.gov/web/menu/patdata.html. e-file.
ISSN: 0098-1133.
DT Patent
LA English
L12 ANSWER 35 OF 36 SCISEARCH COPYRIGHT 2003 ISI (R)
AN 97:911468 SCISEARCH
GA The Genuine Article (R) Number: YK072
TI Organometallic complexing agents as carriers in **polymer**-based electrodes
AU Chaniotakis N A (Reprint); Tsagatakis J K; Jurkschat K; Willem R
CS UNIV CRETE, DEPT CHEM, ANALYT CHEM LAB, DEPT SENSOR & BIOSENSOR DEV & APPLICAT, IRAKLION 71409, CRETE, GREECE (Reprint); UNIV DORTMUND, LEHRSTUHL ANORGAN CHEM 2, DORTMUND, GERMANY; FREE UNIV BRUSSELS, HNMR, B-1050 BRUSSELS, BELGIUM
CYA GREECE; GERMANY; BELGIUM
SO REACTIVE & FUNCTIONAL POLYMERS, (NOV 1997) Vol. 34, No. 2-3, pp. 183-188.
Publisher: ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS.
ISSN: 1381-5148.
DT Article; Journal
FS PHYS
LA English
REC Reference Count: 16
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L12 ANSWER 36 OF 36 SCISEARCH COPYRIGHT 2003 ISI (R)
AN 91:447564 SCISEARCH
GA The Genuine Article (R) Number: FZ908
TI SELECTIVITIES AND THERMODYNAMIC PARAMETERS OF ALKALI-METAL AND ALKALINE-EARTH-METAL COMPLEXES OF **POLYETHYLENE**-GLYCOL DIMETHYL ETHERS IN METHANOL AND ACETONITRILE
AU VANTRUONG N; NORRIS A R; SHIN H S; BUNCEL E (Reprint); BANNARD R A B; PURDON J G

CS QUEENS UNIV, DEPT CHEM, KINGSTON K7L 3N6, ONTARIO, CANADA; DEF RES ESTAB, DIV PROTECT SCI, OTTAWA K1A 0Z4, ONTARIO, CANADA; DEF RES ESTAB SUFFIELD, DIV DEF SCI, CB DEF SECT, MEDICINE HAT T1A 8K6, ALBERTA, CANADA
CYA CANADA
SO INORGANICA CHIMICA ACTA, (1991) Vol. 184, No. 1, pp. 59-65.
DT Article; Journal
FS PHYS
LA ENGLISH
REC Reference Count: 69